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ABSTRACT: Tyrosine kinase inhibitors (TKIs) of the EGF receptor
(EGFR) have provided a signiﬁcant improvement in the disease
outcome of nonsmall cell lung cancer (NSCLC). Unfortunately,
resistance to these agents frequently occurs, and it is often related to
the activation of the Hedgehog (Hh) and MET signaling cascades
driving the epithelial-to-mesenchymal transition (EMT). Because the
concomitant inhibition of both Hh and MET pathways restores the
sensitivity to anti-EGFR drugs, here we aimed at discovering the ﬁrst
compounds that block simultaneously MET and SMO. By using an
“in silico drug repurposing” approach and by validating our
predictions both in vitro and in vivo, we identiﬁed a set of
compounds with the desired dual inhibitory activity and enhanced
antiproliferative activity on EGFR TKI-resistant NSCLC. The
identiﬁcation of the known MET TKIs, glesatinib and foretinib, as
negative modulators of the Hh pathway, widens their application in the context of NSCLC.
■ INTRODUCTION
Nonsmall cell lung cancer (NSCLC) is the major cause of
cancer-related deaths worldwide.1 The primary reason for this
poor outcome is the presence of metastatic dissemination in a
high proportion of patients at diagnosis. The critical step in the
development of metastasis and acquisition of resistance to
existing cytotoxic and targeted agents, including EGFR-TKIs, is
the epithelial-to-mesenchymal transition (EMT) process. EMT
is characterized by a switch from an epithelial phenotype of
polarized cells, with the expression of epithelial markers such as
E-cadherin, to a mesenchymal phenotype of cells that lack
polarity, that are motile, and have E-cadherin down-regulation.
This phenomenon has been extensively studied, and measures
to reverse EMT are awaited to enhance the therapeutic eﬃcacy
of anticancer drugs against NSCLC.
In this scenario, the Hedgehog (Hh) signaling cascade has
recently emerged as an important mediator of cancer
development and metastatic progression.2 The Hh pathway
regulates these processes through the induction of EMT. This
pathway is comprised of the ligands Sonic, Indian, and Desert
hedgehog (Shh, Ihh, Dhh, respectively), the cell surface protein
Patched (PTCH) and the Frizzled G protein-coupled receptor
(GPCR) Smoothened (SMO). In the absence of Hh ligands,
PTCH inhibits SMO, while, upon ligand binding to PTCH,
SMO is activated, triggering the GLI1 transcription factor,
which in turn migrates into the nucleus, leading to the
expression of Hh-induced genes. Hh has been demonstrated to
be active in human embryogenesis and in tissue repair as well as
in cancer stem cell renewal and survival. This pathway is also
critical for lung development, while its aberrant reactivation is
implicated in cellular response to injury and cancer growth.3,4
Recently, alterations (mutation, ampliﬁcation, mRNA over-
expression) of the gene encoding for SMO have been
investigated in The Cancer Genome Atlas (TCGA) lung
adenocarcinomas by whole exome sequencing and were
observed in 12.2% of lung tumors. The incidence of SMO
mutations was 2.6% and SMO gene ampliﬁcations were found
in 5% of cases.5
Similarly, the overexpression of the receptor tyrosine kinase
MET, also called hepatocyte growth factor receptor (HGFR),
and/or its activation has been demonstrated to be a crucial
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mediator of the EMT process and has been implicated in
resistance to chemotherapy and to anti-EGFR TKIs. Several
MET TKIs inhibitors have been evaluated in phase II/III
clinical studies in NSCLC patients, with controversial results.6
Most probably, blocking MET alone is not suﬃcient to revert
the resistant phenotype as this latter is implicated in several
intracellular interactions and the best way to overcome
resistance is a combined approach, where the concomitant
inhibition of MET and Hh pathways is performed.
In this respect, we have recently demonstrated the
occurrence of SMO gene ampliﬁcation, MET activation, and
a functional interaction of these two signaling pathways in a
model of EGFR-mutated TKI-resistant NSCLC cells.7 In the
same cell model, inhibition of SMO in combination with MET
inhibition signiﬁcantly reduced cancer cell proliferation,
induced apoptosis, blocked the invasive and migratory behavior,
and induced the complete regression of 100% of tumors
xenografted in nude mice.7 Moreover, blockade of Hh pathway
reverted EMT and was also associated with enhanced tumor
sensitivity to cytotoxic agents in EGFR-wild-type NSCLC
models.7 Consistently, recent data demonstrated that aberrant
activation of the Hh pathway represented also a common
feature, along with EMT, in an in vivo model of acquired
resistance to EGFR-inhibitors obtained with a sequence of ﬁrst-
generation (erlotinib), second-generation (afatinib), and third-
generation (osimertinib) EGFR TKIs.8
The synergistic interaction of Hh and MET pathways
strongly supports the rationale for a combined therapy in
order to overcome resistance to EGFR TKIs. On the other
hand, despite the established pharmacological signiﬁcance of
combination therapies, several advantages can be envisaged
with the employment of rationally discovered compounds that
are able to simultaneously hit two diﬀerent pharmacological
targets9 such as a better description of the pharmacokinetic
proﬁle compared to combination therapy, diminished risks of
drug−drug interactions, and a simpliﬁed dosing scheduling. On
the other hand, multitarget compounds might indeed display a
degree of target promiscuity resulting in unexpected adverse
eﬀects that could lead to late attrition in the drug discovery
pipeline. To this end, repurposing of known drugs, with an
already described toxicological proﬁle, might indeed oﬀer an
attractive opportunity in the search of multitarget ligands.10
Figure 1. Interaction ﬁngerprints calculated through docking experiments for SMO antagonists (a) and MET inhibitors (b) with the four SMO
receptor structures. The most frequently contacted residues are labeled. (c) Structures of the MET inhibitors identiﬁed as potential SMO antagonists
along with their IC50 or Kd values. For each MET inhibitor, the reported IC50 or Kd values correspond to the ones indicated in the paper where they
were ﬁrst published. For compound 1, see ref 14; for compounds 2, 4, and 9, ref 15; for compounds 3, 5, 6, 7, 8, 10, 11, and 12, see refs 16−22, and
23, respectively.
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In this context, the aim of the present study was to rationally
discover a set of antiproliferative compounds able to
simultaneously block MET and SMO receptors. To this end,
we wanted to merge the advantages of the drug repurposing
strategy,10 which searches for novel indications, mechanism of
action, and/or pharmacological targets of already existing drugs,
with the predictive power of theoretical docking-based virtual
screening (VS). Through this “in silico drug repurposing
approach”, we selected, among 1911 MET-inhibitors, a set of
12 promising compounds for their potential dual inhibitory
activity against MET and SMO, which were validated in in vitro
and in vivo models of resistance to anti-EGFR TKIs.
This strategy allowed us to identify two compounds that are
currently in clinical trials, as new inhibitors of the Hh pathway,
in addition to the already known AXL and MET inhibitory
properties. The potent antitumor activity in vitro and in vivo in
a NSCLC model of EGFR-acquired resistance potentially
expands the indications for these two drugs.
■ RESULTS
In Silico Identiﬁcation of Known MET Inhibitors as
New SMO Binders. To identify MET inhibitors, which might
show interesting aﬃnities at the SMO receptor and vice versa,
we took advantage of a public domain repository of compound
structures and activity data, the BindingDB database.11 Thus, a
set of 1911 known selective, as well as unselective MET
inhibitors, was virtually docked against the available SMO
receptor X-ray structures by following a protocol that we
recently devised to optimize the performances of structure-
based VS against SMO receptor.12 By following this protocol,
we were able to rank the inspected compounds for their
predicted aﬃnity against the SMO receptor.
A critical step of a VS campaign is the postdocking selection
of the compounds to experimentally test. To this end, we ﬁrst
decided to in silico characterize the theoretical interaction
pattern established by known SMO antagonists and the
published structures for this receptor. Therefore, as happened
for the MET inhibitors, a collection of 412 SMO antagonists
was also obtained by interrogating the BindingDB database.11
Thus, by following the above-mentioned docking protocol for
these latter compounds, the binding pose within the SMO
receptor was calculated. These results were subsequently
analyzed through an interaction ﬁngerprints routine (see
Materials and Methods), thereby allowing us to detect which
SMO residues are predicted to be more frequently contacted by
the known antagonists for this receptor. According to this
inspection, the SMO D384, Y394, R400, and E518 residues are
the most frequently contacted ones. Interestingly, also
mutagenesis experiments outlined the importance of the
above-mentioned residues for SMO antagonist binding.13 The
same interaction pattern was also observed for the docked
MET inhibitors within the SMO receptor, thereby substantiat-
ing our initial design hypothesis. Parts a and b of Figure 1
depict the interaction ﬁngerprints obtained for the two docking
experiments (SMO antagonists against SMO receptor and
MET inhibitors against the same receptor, Figure 1a,b,
respectively). In addition, analysis of the X-ray antagonist/
SMO structures also outlined that N219, F484, and W281
receptor residues provide additional anchoring points for
cocrystallized antagonists.
Thus, in our theoretical model, we further ﬁltered out the
docked MET inhibitors for which no favorable contacts with
the above-mentioned SMO residues were predicted. Of the
remaining 421 compounds, 25 were commercially available and,
of the latter, we decided to select only those whose MET
inhibitory potency and or aﬃnity were reported to be at least in
the midmicromolar regimen. This additional ﬁlter allowed
selecting 12 inhibitors that were ﬁnally purchased from
diﬀerent vendors and then checked for compound composition
and purity (see Supporting Information). The selected
inhibitors along with their reported inhibitory activity and/or
aﬃnity against MET are reported in Figure 1c.
Selected MET Inhibitors Bind and Antagonize SMO
Receptor. The aﬃnity of the selected compounds toward
SMO protein was evaluated by radioligand binding competition
studies using [3H]-cyclopamine ((2′R,3S,3′R,3′aS,6′S,6aS,-
6bS,7′aR,11aS,11bR)-1,2,3,3′a,4,4′,5′,6,6′,6a,6b,7,7′,7′a,8,11,-
11a,11b-octadecahydro-3′,6′,10,11b-tetramethyl-spiro[9H-
benzo[a]ﬂuorene-9,2′(3′H)-furo[3,2-b]pyridin]-3-ol, 13, Sup-
porting Information, Chart S1).24 For this purpose, we used the
EGFR exon 19 deletion mutant (delE746-A750) HCC827-GR
human NSCLC cell line made resistant to geﬁtinib in vitro,
which we previously characterized for SMO and MET
expression.7 The HCC827-GR cell line presents SMO gene
ampliﬁcation and MET pathway overexpression and activation.7
In particular, NGS analysis of this cell line showed a 47% allelic
frequency of V404 M mutation in the SMO gene as compared
to the parental HCC827, which showed an allelic frequency of
0.1%, indicating the selection of an SMO mutated resistant
clone during acquisition of resistance to geﬁtinib. The aﬃnity
dissociation constant (Kd) of [
3H]-13 in HCC827-GR cells
overexpressing the SMO receptor was 36.9 ± 8.9 nM and a
Bmax of 1567 ± 61 fmol/mg, as obtained by saturation binding
studies (Figure 2).
The SMO antagonist vismodegib (2-chloro-N-[4-chloro-3-
(2-pyridinyl)phenyl]-4-(methylsulfonyl)benzamide, 14,25 Sup-
porting Information, Chart S1) showed a Ki value of 12.2 ± 1.7
nM in accordance with literature data.26 Some of the
compounds (compounds 1, 2, 4, and 6) were not able to
completely displace the radiolabeled ligand when tested at a 10
μM concentration. On the contrary, compounds 3, 5, and 7−12
Figure 2. SMO binding analysis. Saturation assay of [3H]-13 binding
to HCC827-GR cells. Cells were incubated 4 h at RT in binding buﬀer
containing increasing concentrations of [3H]-13. Nonspeciﬁc binding
was determined in the presence of 25 μM of compound 14. Scatchard
plot analysis of the speciﬁc binding. Data are means ± SEM (n = 3) of
a representative experiment over three independent experiments. The
ability of each of the 12 potential dual inhibitors to displace 25 nM
[3H]-13 speciﬁc binding is reported in Table 1.
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demonstrated the ability to compete with the [3H]-13 for the
SMO binding site with an aﬃnity in the nanomolar range
(Table 1). In particular, compounds 5 and 11 were
demonstrated to be comparably eﬃcient in inhibiting MET
and binding SMO. For these latter inhibitors, we also
demonstrated that a similar aﬃnity was recorded for the wild-
type SMO receptor (Figure 2b), indicating that the V404 M
SMO mutation does not aﬀect drug aﬃnity. Figure 3 reports
the binding mode of compounds 3, 5, and 7−12 in the SMO
receptor (see Figures S1−S8 in Supporting Information for the
2D diagrams of the calculated complexes).
Because GLI1 is a SMO regulated transcription factor,27 we
tested the functional signiﬁcance of treatment with MET
inhibitors that demonstrated the highest ability to displace 13
from binding to the SMO receptor on GLI1 activity by using a
GLI1-responsive promoter within a luciferase reporter
expression vector. In particular, we performed a dose-
dependent analysis of luciferase activity in HCC827-GR cell
line (Figure 3). Treatment with 2 μM (Figure 4a) or 60 μM
(Figure 4b) of each compound resulted, respectively, in a 25−
50% and in a 10−100% decrease in GLI1-responsive promoter
compared with the HCC827-GR untreated cells (p < 0.001).
These data demonstrate that the tested MET inhibitors have
a SMO antagonist activity in a concentration-dependent
manner. Furthermore, to test if the eﬀect of the selected
compounds on GLI1 activity was mediated by SMO
antagonism, we analyzed the ability of the SMO agonist SAG
(100 nM) [N-methyl-N′-(3-pyridinylbenzyl)-N′-(3-
chlorobenzo[b]thiophene-2-carbonyl)-1,4 diaminocyclohex-
ane]28 to revert this eﬀect. Interestingly, in the presence of
SAG, the induced inhibition of GLI1 activity was completely
reverted in almost all treatments at a 2 μM concentration of
Table 1. Experimental Binding Aﬃnity of Compounds 1−14
towards V404M Mutant SMO Receptor in HCC827-GR
Cells and of Compounds 5 and 11 on WT SMO Receptor in
HEK293T Cellsa
compd Ki V404 M SMO (nM) Ki wt SMO (nM)
1 nd
2 nd
3 168.1 ± 21.9 nd
4 nd
5 53.1 ± 9.9 41.7 ± 8.2
6 nd
7 46.5 ± 6.3 nd
8 187.8 ± 36.9 nd
9 50.4 ± 11.8 nd
10 46.2 ± 11.7 nd
11 66.8 ± 7.0 59.7 ± 9.6
12 87.6 ± 12.4 nd
13 51.0 ± 8.4 nd
14 12.2 ± 1.7 nd
and: not determined.
Figure 3. Predicted binding pose of compound 3, 5, and 7−12 in the SMO X-ray structure. Compounds are represented as green sticks, while
receptor as orange sticks and transparent white ribbons. H-bonds are represented as dashed yellow lines.
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compounds 3, 5, and 7−12 (p < 0.01) (Figure 4a) and partially
reverted at a 60 μM concentration (Figure 4b), conﬁrming that
the selected MET inhibitors antagonize the SMO receptor
function.
Dual MET/SMO Inhibitors Are Potent Antiproliferative
Agents in EGFR-TKI Resistant Human NSCLC. We then
selected, among the 12 potential dual inhibitors, compounds 5
and 11 as the most active MET inhibitors with the most potent
activity also on SMO. Moreover, we also kept compounds 6
(signiﬁcant inhibitory activity against MET and no binding at
SMO receptor) and 9 (weak MET inhibitor and nanomolar
aﬃnity for SMO) as negative controls. Of interest, compound 5
was identiﬁed as glesatinib (N-[(3-ﬂuoro-4-{[2-(5-{[(2-
methoxyethyl)amino]methyl}pyridin-2-yl)thieno[3,2-b]-
pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-ﬂuorophenyl)-
acetamide),17 MGCD265,54 Mirati Therapeutics), a tyrosine
kinase inhibitor of MET and AXL, and compound 11 as
foretinib (N1′-[3-ﬂuoro-4-[[6-methoxy-7-(3-morpholinopro-
poxy)-4-quinoly l]oxy]phenyl]-N1-(4-ﬂuorophenyl)-
cyc lopropane-1 ,1-d icarboxamide , XL880, Exe l ix i s ,
GSK1363089, GlaxoSmithKline),22 known as a MET and
VEGFR2 inhibitor, with activity against AXL.
We analyzed the activity of 5 and 11 in the EGFR-mutated
HCC827-GR NSCLC cells with the already described
ampliﬁcation of SMO and overexpression of MET and
displaying a typical mesenchymal behavior.7 In this model, as
already demonstrated, activation of AXL (phospho-AXL),
which is a known pathway responsible for the acquisition of
resistance to anti-EGFR TKIs and mediator of EMT,29 and
another signaling pathway potentially activated as a resistance
mechanism, was not signiﬁcantly high as compared to sensitive
cell models.7
We ﬁrst evaluated the antiproliferative eﬀects at diﬀerent
concentrations of 5 and 11 by using an MTT assay. To
compare the eﬀects of each compound with those obtained
with speciﬁc SMO and MET inhibitors, we also treated the
same cancer cells with sonidegib (N-[6-[(2S,6R)-2,6-dimethyl-
morpholin-4-yl]pyridin-3-yl]-2-methyl-3-[4-(triﬂuoromethoxy)-
phenyl]benzamide, NVP-LDE225, SMO antagonist with no
reported inhibitory activity against MET, Novartis, 15,
Supporting Information, Chart S1)30 and PHA-665752
((3Z)-5-[(2,6-dichlorophenyl)methylsulfonyl]-3-{[3,5-dimeth-
yl-4-[(2R)-2-(pyrrolidin-1-ylmethyl)pyrrolidine-1-carbonyl]-
1H-pyrrol-2-yl]methylidene}-1H-indol-2-one, MET inhibitor
with no reported activity against SMO, Pﬁzer, 16, Supporting
Information, Chart S1)31 as single agents and in combination.
In addition, down-regulation of MET and SMO mRNA levels
was performed with silencing-RNA technology. By using drug
concentrations ranging from 0.01 to 5 μM, treatment with 5 or
11 resulted in a dose-dependent inhibition of cancer cell
growth and showed the lowest IC50 values (0.08 and 0.5 μM,
respectively, for 5 and 11) (Figure 5a).
Compounds 6 and 9 resulted in higher IC50 values, while the
selective inhibition of MET or SMO, by pharmacological or
mRNA silencing approaches, did not exert comparable eﬀects.
Of interest, 5 and 11 performed even better than combined
treatment with 15 and 16 or the double silencing of SMO and
MET in resistant cells.
We further asked whether the increased antiproliferative
eﬀect induced by 5 and 11 would be the result of an increased
apoptosis. Therefore, we analyzed the induction of apoptosis in
the EGFR-mutated HCC827-GR cell line after 72 h treatment.
As shown in Figure 5b, ﬂow cytometric analysis revealed that
treatment with compound 5 and 11 signiﬁcantly increased by
several-fold the percentage of apoptotic cells in all tested cell
lines. For instance, in HCC827-GR cells, 5 induced the higher
apoptotic rate with a 62% and 84% apoptotic rate at 0.1 and 0.5
μM, respectively (Figure 5b), compared to the apoptotic rate of
50 and 65% obtained with the combination of 15 and 16 (P <
0.001; Figure 5b).
Interestingly, comparative antiproliferative activities were
recorded when testing 5 and 11 on an EGFR-wild-type H1299
adenocarcinoma NSCLC line, which overexpresses both SMO
and MET receptors and is resistant to cisplatin treatment (see
Supporting Information). Nevertheless, it should be mentioned
that in this case the antiproliferative activity exerted by 5 and 11
should not only be ascribed to the concurrent inhibition of
SMO and MET. Indeed, in our previous inspection,7 we
demonstrated that, in the same cell line, treatment with 15 and
16 (MET inhibitor and SMO antagonist, respectively) did not
result in an eﬃcient antiproliferative eﬀect. In this respect, it
should be outlined that while 5 and 11 demonstrated to be also
potent AXL inhibitors, 15 is unable to inhibit this latter kinase.
Therefore, it could be postulated that in the EGFR wild-type
H1299 adenocarcinoma NSCLC line, the triple MET/SMO/
AXL inhibition might be responsible for the enhanced
antiproliferative activity of 5 and 11. Indeed, the additional
AXL inhibitory potency was also demonstrated to be
responsible for the antiproliferative activity of 11 against
HER2-positive breast tumor cells.32 A further support for this
hypothesis is provided by a recent paper by Qu et al.,
demonstrating that AXL is indeed overexpressed in the H1299
adenocarcinoma NSCLC line and that silencing of this kinase
Figure 4. GLI1-driven luciferase expression in HCC827-GR cells
during treatment with compounds 3, 5, and 7−12 at 2 (a) and 60 μM
(b) and in combination with SAG at a concentration of 100 nM. CTR
bars represent the response obtained for HCC827-GR untreated cells.
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inhibited cell proliferation and migration.33 This might also
explain why in the HCC827-GR cell lines 5 and 11 are slightly
more active than the concurrent treatment with 15 and 16
(Figure 5).
To study the inﬂuence of 5 and 11 on the activation/
expression of key signaling mediators, we further characterized
the eﬀects of experimental compounds on the intracellular
signaling by Western blotting. We used diﬀerent doses
according to the IC50 of each drug. As illustrated in Figure 6,
treatment of HCC827-GR cells with 5 and 11, for 72 h,
eﬀectively blocked SMO and MET activation, conﬁrming the
dual inhibitory ability of these drugs. In addition, while not
aﬀecting the total MAPK and AKT protein levels, treatment
with 5 and 11 markedly decrease the activated forms of both
proteins, conﬁrming our previous results7 on the cooperation of
Hh with MET pathway to the activation of both MAPK and
AKT signaling pathways. In addition, vimentin expression,
induced during the acquisition of geﬁtinib resistance, was
signiﬁcantly decreased after 5 or 11 treatment, suggesting that
the Hh and MET pathways represent a key mediator of EMT in
this model.
Dual MET/SMO Modulators Inhibit Resistant Human
NSCLC Tumor Growth in Vivo. We previously demonstrated
that the in vivo blockade of the Hh signaling pathway alone, or
alternatively the sole MET pathway, is not suﬃcient to cause a
signiﬁcant delay in tumor growth, whereas the concurrent
inhibition of both pathways resulted in a substantial antitumor
activity.7 We, therefore, tested the eﬃcacy of compounds 5 and
11, as dual inhibitors of SMO and MET, to overcome the
acquisition of resistance to the ﬁrst-generation EGFR TKIs.
Thus, HCC827 NSCLC tumor xenografts were implanted in
Figure 5. Biological activity of experimental compounds on the HCC827-GR NSCLC cell line. (a) MTT proliferation assay performed on NSCLC
HCC827-GR cells with the indicated treatments. The results are the average ± SD of three independent experiments, each done in triplicate. (b)
Apoptosis was evaluated as described in the Experimental Section with annexin V staining in HCC827-GR cancer cells, which were treated with the
indicated concentration of drugs. Columns, mean of three identical wells of a single representative experiment; bars, top 95% conﬁdence interval.
Figure 6. Eﬀects on intracellular pathways by experimental
compounds. Western blotting analysis of Hh and MET pathways
following treatment with the indicated concentration of compound 5
and 11 on HCC827-GR NSCLC cell line. Tubulin was included as a
loading control.
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nude mice and treated with geﬁtinib (N-(3-chloro-4-ﬂuoro-
phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-
amine, 17, Supporting Information, Chart S1).34 Then,
following tumor regrowth as resistance to 17 was acquired,
mice were randomized to receive 5 or 11 ± 17 (Figure 7).
Indeed, treatment with 5 or 11 as single agents caused a
signiﬁcant decrease in tumor size. However, combined
treatments of 17 plus 5 and 17 plus 11 signiﬁcantly suppressed
HCC827-17 resistant tumor growth, suggesting that keeping
the EGFR blockade during inhibition of SMO and MET is an
eﬀective strategy to overcome resistance to ﬁrst-generation
EGFR TKIs (Figure 7).
Subsequently, we also wanted to check if a similar strategy
might be applied to EGFR-mutated NSCLC models with
acquired resistance to third-generation EGFR inhibitors. We,
therefore, performed a similar in vivo experiment inducing
resistance to the third-generation inhibitor, osimertinib (N-(2-
{[2-(dimethylamino)ethyl]-(methyl)amino}-4-methoxy-5-{[4-
(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)-
acrylamide, AZD9291, AstraZeneca, 18, Supporting Informa-
tion, Chart S1)35 because analysis on resistant 18-tumors
harvested from treated mice, similarly to tumors with acquired
resistance to 17, evidenced an activation of both Hh and MET
pathways, highlighting the role of those two pathways also in
the resistance of third-generation inhibitors.8 Therefore, mice
whose tumors are resistant to 18 treatment were randomized to
treatment with 5 or 11 as single agents or a combination of 5 or
11 with 18 (Figure 7). Interestingly, also HCC827-osimertinib
resistant tumors resulted in being particularly sensitive to the
dual inhibition of MET and SMO and, to a greater extent, to
the triple inhibition of MET/SMO/EGFR (Figure 7).
■ CONCLUSIONS
Our previous work7 has highlighted the functional interaction
of Hh and MET pathways and the importance of blocking both
signaling pathways to revert EMT and enhance tumor
sensitivity to anti-EGFR NSCLC models.
Stimulated by these ﬁndings, herein we were challenged to
discover the ﬁrst dual SMO/MET modulators that are able to
overcome resistance to therapy in human NSCLC. Indeed,
while these two pharmacological targets are unrelated from the
structural point of view, they are able to recognize chemotypes
that share common structural features. Thus, taking advantage
of the published X-ray structures of the antagonist-bound SMO
receptor, a stepwise protocol of receptor-based VS was
undertaken to in silico select, among a set of known MET
inhibitors, the best candidates that can be recognized by the
SMO receptor orthosteric binding site. Of the 12 tested
compounds, eight demonstrated the ability to displace 13 with
nanomolar potency. These SMO binders were subsequently
assayed in functional studies, allowing the demonstration of
their capacity to inﬂuence the SMO activation status in a
concentration-dependent manner. Moreover, the eﬃcacy of
these compounds was reverted by the cotreatment with a
known SMO agonist, allowing us to further substantiate the
antagonist activity of the eight compounds. To the best of our
knowledge, this is one of the ﬁrst examples in which
computational methods were successfully employed to ration-
ally discover multitarget compounds hitting proteins belonging
to phylogenetically and structurally distant families (namely the
Frizzled class F) GPCRs and class IV tyrosine kinases receptors
(TKR). Indeed, it should be mentioned that binding and
functional assays were conﬁned to the set of 25 compounds
that were commercially available. Indeed, a large number of
Figure 7. Eﬀects of the treatment with compound 5 or 11 alone or in combination with 17 or 18 in human NSCLC tumor xenografts resistant to the
EGFR-TKI. Mean tumor volumes of human NSCLC tumor xenografts made resistant to (a) 17 or (b) 18 and randomized to treatment with the
indicated drugs and combinations. Data represent the average (SD). Student t test was used to compare tumor sizes among diﬀerent treatment
groups at day 21 following the start of treatment.
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MET inhibitors have been published and screened through our
theoretical protocol that would deserve further experimental
testing as SMO antagonists but were not considered in the
present study because of their unavailability on the market. In
this context, this study should also stimulate the biological
evaluation of these latter compounds.
Prompted by these encouraging data, cell-based experiments
were performed in NSCLC cell lines made resistant to the
EGFR-TKI 17. Strikingly, in this model, 5 and 11 were even
more eﬀective in achieving an antiproliferative eﬀect than the
combination treatment with a pure MET inhibitor and the
SMO antagonist as well as the double silencing of the two
target proteins. This result might be explained by the ability of
5 and 11 to inhibit AXL TKI. In this respect, both drugs were
also the most active apoptosis inducers. When tested in vivo, 5
and 11 alone signiﬁcantly decreased the tumor size of human
NSCLC xenografts resistant to the EGFR-TKI, and this eﬀect
was potentiated by the coadministration with 17. This
demonstrates that, at least in our model, the triple inhibition
of SMO, MET, and EGFR is indeed the most eﬀective strategy
to circumvent drug resistance to EGFR TKIs. The same data
were also achieved by cotreatment with the selected drugs and
third-generation EGFR TKIs, 18.
Of note, our ﬁndings allow unraveling previous results
achieved for 5 and 11. In particular, it has been recently
reported that 5, when used in combination with erlotinib
(EGFR-TKI) in a gastric cancer model, impairs the glycolysis
pathway also by inhibiting the 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase 3 (PFKFB3) enzyme, thereby
suggesting a novel mechanism of action for this drug.36 In
addition, it has been recently reported that the Hh signaling
promotes glucose utilization and glycolysis, thereby accelerating
cell proliferation in breast cancer cells, by positively modulating
the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3
(PFKFB3) phosphorylation.37 In this scenario, our data
reconcile the negative modulation of cancer glycolysis exerted
by 5 with its antagonist activity on SMO receptor.
On the other hand, 11 has been demonstrated to eﬃciently
decrease tumor cell proliferation and to induce apoptosis in
Hh-driven medulloblastomas. These data were ﬁrst explained
with the ability of this drug to inhibit MET that was proposed
to be a marker of the aforementioned tumor.38 Herein we
suggest that the eﬃcient antiproliferative activity displayed by
11 should also be ascribed to a direct interaction with the SMO
receptor.
In conclusion, in this work, the tandem application of
predictive theoretical studies and in-depth in vitro and in vivo
evaluation allowed us to identify from a large number of MET
inhibitors those that can negatively modulate the SMO receptor
and achieve superior antiproliferative eﬀects in a model of
resistant NSCLC tumor. In this context, the identiﬁcation of 5
and 11 as negative modulators of the Hh pathway widens the
range of action of these drugs in the context of NSCLC
improving the already known AXL and MET targeting activity.
■ EXPERIMENTAL SECTION
Molecular Modeling. Proteins and ligands setup: The structure of
the SMO receptor in complex with the antagonists (4-benzyl-
piperazin-1-yl)-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethylene)-
amine39 (SANT-1, PDB 4N4W),40 2-(6-(4-(4-benzylphthalazin-1-
yl)piperazin-1-yl)pyridin-3-yl)propan-2-ol41 (ANTA XV, PDB
4QIM),40 4-ﬂuoro-N-methyl-N-(1-(4-(1-methyl-1H-pyrazol-5-yl)-
phthalazin-1-yl)piperidin-4-yl)-2-(triﬂuoromethyl)benzamide42
(LY2940680, PDB 4JKV),43 and 13 (PDB 4O9R)44 were downloaded
from the Protein Data Bank and prepared for docking calculations
using the “Protein Preparation Wizard” panel of Schrödinger
molecular modeling package.45 In particular, using the “pre-process
and analyze structure” tool, the bond orders and disulﬁde bonds were
assigned, all the hydrogen atoms were added, and water molecules
were deleted. Using Epik 2.0, a prediction of the side chains hetero
groups ionization and tautomeric states was performed.46 An
optimization of the hydrogen-bonding network was performed using
the “H-bond assignment” tool. Finally, using the “impref utility”, the
positions of the hydrogen atoms were optimized by keeping all the
heavy atoms in place.
A database of known MET ligands (1911 compounds) was
subsequently prepared by interrogating the BindingDB database.11
Ligands were prepared for docking using LigPrep.47 Hydrogen atoms
were added, ionizations states were generated, and tautomers were
generated to prepare the required structures. All structures were then
subjected to minimization using the OPLS-2005 force ﬁeld. The same
preparation was attained for the database of the known SMO
antagonists downloaded from the BindingDB site.11
Docking Calculations. According to the results of our very recent
retrospective study, the employment of the AutoDock Vina docking
software48 when used against the ensemble of all the four receptors
gave the best results in terms of enrichment factors (EF) when
considering the lowest percentages of the ranked database (25%).12
AutoDock Vina performances and accuracy are assured by a
Lamarckian algorithm and an empirical binding free energy force
ﬁeld. Before the actual docking calculations could be run, both the
database of ligands and the receptors had to be converted to the pdbqt
format. The latter is very similar to a standard pdb but it includes “Q”
(partial charges) and “T” atom types. Preparing the structures involves
ensuring that its atoms are assigned the correct atom types, adding
Gasteiger charges if necessary, merging nonpolar hydrogens, detecting
aromatic carbons, and setting up the “torsion tree” in the case of
ligands. Thus, the python scripts prepare_receptor4.py and prepar-
e_ligand4.py, part of MGLTools,49−51 were employed by applying the
standard settings. After the preparation, the docking was performed
using the default settings of Vina, setting a box whose center and
dimensions were identical to the one used in our previous work.12
Results of these calculations produced four diﬀerent rankings based on
the predicted binding free energy (herein referred to as ΔGVINA), one
for each docking attained on the four receptor structures, which were
subsequently uniﬁed using a parallel selection method. This selection
method resulted in a ranking of the screened compounds in which
ΔGVINA values ranged from −6.5 to −14.8 kcal/mol.
Interaction ﬁngerprints and interaction matrices of the SMO ligands
against SMO receptors and MET ligands against the same receptors
were calculated by employing a routine of the Schröedinger 2015
release. The pose ﬁlter routine of the same release was used to count
the number of interactions predicted for the MET compounds against
D384, Y394, R400, E518, N219, F484, and W281 residues.
The ﬁngerprint-based algorithm was used to cluster the 511 MET
ligands in order to further reﬁne them into 421 compounds. The
canvas similarity and clustering, which is also part of the Schrodinger
suite, was employed by applying the following settings: the eighth
atom typing scheme for the ﬁngerprinting (atoms distinguished by
ring size, aromaticity, HB acceptor/donor, ionization potential,
whether terminal, whether halogen; bonds distinguished by bond
order), Tanimoto as the similarity metric, and average as linkage as the
clustering method. The same method (i.e., canvas similarity using the
eighth atom typing scheme for the ﬁngerprinting and Tanimoto as the
similarity metric) was also used to evaluate the structural similarity
between each of the 12 ﬁnal compounds and any of the SMO
antagonist reported in the BindingDB database.11 Table S2 in
Supporting Information reports the Tanimoto similarity index
between the 12 compounds and the most similar SMO antagonist.
These values range from 7.8% to 32%, demonstrating that the selected
ligands are structurally unrelated to the SMO antagonists described so
far.
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All of the pictures were rendered with the UCSF Chimera package
from the Resource for Biocomputing, Visualization, and Informatics at
the University of California, San Francisco.37
Prior to biological evaluation, the 12 compounds were screened for
Pan Assay Interference Compounds using the PAINS-Remover web
server (http://www.cbligand.org), which is a data analysis tools
implemented for removal of PAINS compounds. All compounds
passed this ﬁltering with the exception of compound 7 and 9.
Compound 7 features an anil_di_alk_A substructure that is suggested
to interfere with AlphaScreen technology, possibly through eﬃcient
quenching of singlet oxygen.52 In our case, we performed a radioligand
displacement binding assay so no interference is expected. Compound
9 features an imine_one_isatin substructure, which was found to
interfere sometimes with the AlphaScreen technology “for reasons
unknown”,52 as stated by the authors. Also in this case, the tested
ligand should not interfere with the implemented radioligand
displacement binding assay. On the basis of NMR and MS analysis,
all tested compounds have a purity ranging from 96 to 98%.
Cell Lines and Drugs. The human NSCLC HCC827 cell line was
provided by American Type Culture Collection (ATCC, Manassas,
VA, USA) and maintained in RPMI-1640 (Sigma-Aldrich, Saint Louis,
MO, USA) medium supplemented with 10% fetal bovine serum (FBS;
Life Technologies, Gaithersburg, MD) in a humidiﬁed atmosphere
with 5% CO2. The identity of all cell lines was conﬁrmed by STR
proﬁling (Promega, Madison, WV, USA) on an ad hoc basis prior to
performing experiments. HCC827-GR (geﬁtinib resistant) cell line
was obtained in vitro, as previously described.7 Brieﬂy, over a period of
12 months, HCC827 cells were continuously exposed to increasing
doses of 17, starting from an IC50 dose that represented the dose to
inhibit the growth of 50% of cells. HCC827-GR cells were maintained
in culture with the maximum 17 dose that allowed cellular
proliferation. The identity of cells was veriﬁed by STR proﬁling
(Promega) on an ad hoc basis prior to performing experiments and
repeated for all cell lines after a majority of the experiments were
performed. Drugs geﬁtinib and sonidegib were purchased from Selleck
Chemicals (Selleckchem, Houston, TX, USA). 18 was generously
provided by Astra Zeneca.
SMO Radioligand Binding Assays. Prior to binding experiments,
all purchased compounds were analyzed to conﬁrm the sample
composition by LC/MS and 1H NMR experiments. The binding
experiments were performed as previously described with few
modiﬁcations.26 Brieﬂy, HCC827-GR cells expressing V404 M SMO
receptors were grown in 24-well plates (100000 cells/well) and ﬁxed
with 4% (v/v) formaldehyde/PBS for 20 min at room temperature
(RT). Cells were subsequently incubated for 4 h at RT in binding
buﬀer (Hanks Balanced Salt Solution (HBSS) without Ca2+ and Mg2+
with glucose 1 g/L). Saturation binding experiments were performed
using diﬀerent [3H]-13 (American Radiolabeled Chemicals, Inc. Art.
1473 a.s. 20 Ci/mmol) concentrations ranging from 0.1 to 500 nM; in
competition binding experiments cells were incubated with 25 nM
[3H]-13 and diﬀerent concentrations of the compounds. Nonspeciﬁc
binding was determined in the presence of 25 μM of compound 14.
Incubations were terminated by rapid washing with 1 mL of binding
buﬀer for three times. Then, the bound [3H]-13 was extracted in 200
μL of 0.1 N NaOH for 12 h and neutralized with 200 μL of 0.1 N HCl.
The amount of [3H]-13 in the extracts was measured using a
scintillation counter. For the active compounds, the IC50 values were
determined and Ki values were derived in accordance with the
equation of Cheng and Prusoﬀ.
The aﬃnity of the compounds for the wild-type SMO was
performed as previously described with few modiﬁcations.26 Brieﬂy, 15
μg of HEK293T-WT SMO membranes (Multispan Inc., Cod.
MC1442; Kd = 20 nM; Bmax = 6.2 pmol/mg protein) were incubated
for 4 h at RT in binding buﬀer (HEPES 50 mM, MgCl2 5 mM and
BSA 0.02%) containing 25 nM [3H]-13 (American Radiolabeled
Chemicals, Inc. Art. 1473 a.s. 20 Ci/mmol) and diﬀerent
concentrations of the compounds. Nonspeciﬁc binding was
determined in the presence of 25 μM of compound 14. The bound
radioactivity was separated by rapid ﬁltration through GF/C glass ﬁber
ﬁlters presoaked for 2 h in 0.3% polyethylenimine pH 13.0 and washed
three times with 4 mL of ice-cold phosphate-buﬀered saline with
0.01% Triton X-100, pH 7.0. Radioactivity was measured by liquid
scintillation spectrometry. Dose−response curves are reported in
Supporting Information, Figures S8 and S9.
Luciferase Assay. Here, we performed GLI1 luciferase assay to
test the inﬂuence of selected compounds on GLI1 activity in HCC827-
GR cells by using the Dual-Luciferase Assay system (Promega),
following the manufacturer’s protocol. For each experiment, a total of
5 × 105 cells were seeded in FBS-free medium in 24-well plates and
transfection started when cells reach a conﬂuency of 50%. We
cotransfected the cells with the GLI1-Luc reporter plasmid (400 ng/
well), kindly provided by Dr. Mariolina Castellone53 (University of
Naples Federico II) and pRL-TK, Renilla reporter, encoding the
Renilla luciferase (Promega), to normalize the results. In GLI1
reporter vector, the transcription of Fireﬂy luciferase gene is under the
control of a promoter region speciﬁc for the transcription factor GLI1,
so GLI1 luciferase activity correlates with the binding of GLI1 to its
promoter region; in control reporter, Renilla luciferase activity
depends on a constitutive promoter (thymidine kinase). The
transfection was done in triplicate using Lipofectamine 2000 (provided
by Thermo Fisher Scientiﬁc) as transfection reagent according to
manufacturer’ instructions. The medium of transfection was replaced
after 8 h with culture medium, containing the indicated MET ligands
or without the SMO agonist SAG (100 nM) [N-methyl-N′-(3-
pyridinylbenzyl)-N′-(3-chlorobenzo[b]thiophene-2-carbonyl)-1,4-dia-
minocyclohexane], purchased from Sigma-Aldrich.
Fireﬂy luciferase is a protein from Photinus pyralis that reacts with its
substrate (beetle luciferin, ATP, magnesium, and molecular oxygen),-
creating luminescence, measured by the luminometer Autolumat LB
953 (EG&G, Berthold, Bad Wildbad, Germany). According to the
protocol of the kit Dual-Luciferase Reporter Assay System (Promega),
after about 48 h from transfection, we removed the medium and
washed once with PBS. Then, we added 100 μL of lysis buﬀer 1× in
each well, shaking for 20 min at RT, and ﬁnally scraped.
For the measurement of GLI1 luciferase activity, we mixed by
pipetting 30 μL of lysated cells and 30 μL of Luciferase Assay Reagent,
containing its substrate for reaction. After the reading at luminometer
and the record of data, we added 30 μL of Stop and Glo Reagent,
which blocked GLI1 induced Fireﬂy luciferase signal and contained
Renilla luciferase substrate and repeated the luminometer measure-
ment to obtain the control values. For the analysis of data, we
calculated the average values of GLI1 luciferase signal, normalized to
Renilla luciferase values, and represented the results as fold change
with respect to control cells and cells transfected with the empty
vector; results were the average of three independent experiments.
Protein Expression Analysis. Protein lysates were obtained by
homogenization in RIPA lysis buﬀer (0.1% sodium dodecyl sulfate
(SDS), 0.5% deoxycholate, 1% Nonidet, 100 mmol/L NaCl, 10 mmol/
L Tris-HCl (pH 7.4), 0.5 mmol/L dithiothreitol, and 0.5%
phenylmethylsulfonyl ﬂuoride, protease inhibitor cocktail (Hoﬀ-
mann-La Roche), and clariﬁcation by centrifugation at 14000 rpm
for 10 min a 4 °C. Cancer cells were lysed with Tween-20 lysis buﬀer
(50 mmol/L HEPES, pH 7.4, 150 mmol/L NaCl, 0.1% Tween-20,
10% glycerol, 2.5 mmol/L EGTA, 1 mmol/L EDTA, 1 mmol/L DTT,
1 mmol/L phenylmethylsulfonyl ﬂuoride, and 10 μg/mL of leupeptin
and aprotinin). Protein lysates containing comparable amounts of
proteins, estimated by a modiﬁed Bradford assay (Bio-Rad), were
subjected to Western blot analysis as previously described.7
Immunocomplexes were detected with the enhanced chemilumines-
cence kit ECL plus, by Thermo Fisher Scientiﬁc (Rockford, IL).
Desired proteins were probed with corresponding antibodies. Primary
antibodies for Western blot analysis against p-MAPK44/42 (Thr202/
Tyr204), MAPK44/42, p-AKT (Ser473), AKT, p-MET (Tyr1234/
1235), MET, SMO, and GLI1 were obtained from Cell Signaling
Technology; monoclonal anti-α-tubulin antibody (T8203) from Sigma
Chemical Co. The following secondary antibodies from Bio-Rad were
used: goat antirabbit IgG and rabbit antimouse IgG. Immunoreactive
proteins were visualized by enhanced chemiluminescence (ECL plus;
Thermo Fisher Scientiﬁc). Each experiment was done in triplicate.
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Cell Proliferation Assays. Cancer cells were seeded in 96-
multiwell plates and were treated with diﬀerent doses of indicated
drugs for 72 h. Cell proliferation was measured with the MTT assay, as
previously described.7 IC50 values were determined by interpolation
from the dose−response curves. Results represent the median of three
separate experiments, each performed in quadruplicate. Synergism was
calculated with ComboSyn software, ComboSyn Inc., Paramus, NK.
07652 USA.
RNA Silencing. The small inhibitor duplex RNAs (siRNA) (ON-
target plus SMARTpool) siSMO, siMET, and siCONTROL Non-
targeting Pool (no. D-001206-13-05), used as a negative (scrambled)
control, were provided from Dharmacon (Lafayette, CO). Cells were
transfected with 100 nM siRNAs using Dharmafect reagent following
manufacturer’s instructions. The day before transfection, the cells were
plated in 35 mm dishes at 40% of conﬂuence in medium supplemented
with 5% FBS without antibiotics. Where necessary, cells were treated
with diﬀerent compounds, as previously described; 24 h before
harvesting and cell proliferation or Western blot analysis were then
performed.
Assessment of Apoptosis. Apoptosis was detected by ﬂow
cytometry via the examination of altered plasma membrane
phospholipid packing by lipophilic dye annexin V as described
elsewhere.7 Brieﬂy, treated cells were harvested by trypsin, washed
twice with PBS, and were then resuspended in binding buﬀer at a
concentration of 1 × 106 cells/mL according to the manufacturer’s
instruction. Thereafter, 5 μL of annexin V-FITC and 5 μL of
propidium iodide were added into 100 μL of cell suspension and
incubated for 30 min at room temperature in the dark. After adding
400 μL of binding buﬀer, labeled cells were counted by ﬂow cytometry
within 30 min. All early apoptotic cells (annexin V, positive; propidium
iodide, negative), necrotic/late apoptotic cells (double positive), as
well as living cells (double negative), were detected by FACSCalibur
ﬂow cytometer and subsequently analyzed by Cell Quest software
(Becton Dickinson). Argon laser excitation wavelength was 488 nm,
whereas emission data were acquired at wavelength 530 nm (FL-1
channel) for FITC and 670 nm (FL-3 c3 channel) for propidium
iodide.
In Vivo Experiments. The 4−6-week old female balb/c athymic
(nu/nu) mice were purchased from Charles River Laboratories. The
research protocol was approved and mice were maintained in
accordance with the Institutional Guidelines of the University of
Campania Luigi Vanvitelli Animal Care and Use Committee. Mice
were acclimatized for 1 week before being injected with cancer cells
and injected subcutaneously with 107 HCC827 cells that had been
diluted in 200 μL of Matrigel (Corning Life Sciences, MA, USA), 1:1
in the culture medium. For induction of resistance to 17 or 18, when
tumors reached a mean volume of 150 mm3, mice were treated with
escalating doses of 17 (from 18.7 to 150 mg/kg/day: 3 weeks with
18.7 mg/kg/day, 3 weeks with 37.5 mg/kg/day, 3 weeks with 75 mg/
kg/day, and last the 3 weeks with 150 mg/kg/day) or 198 (with the
same protocol of escalating doses every 3 weeks: 5 mg/kg/day for the
ﬁrst 3 weeks, 10 mg/kg/day for following 3 weeks, 17.5 mg/kg/day for
subsequent 3 weeks, and 25 mg/kg daily for last 3 weeks orally) over 4
months to derive 17/18-resistant tumors (deﬁned as >25% regrowth
from max reduction). At the end of treatment period, resistant tumors
were randomized into one of the following four arms: control, 5, 11,
17/18 plus 5, and 17/18 plus 11. 17 and 18 were continued at
maximum dose reached before resistance, and 5 and 11 were used as
single agents and in combination at ﬁxed doses of 15 and 20 mg/kg/
day orally, respectively. Body weight and tumor volume were
monitored on alternate days. Tumor volume was measured using
the formula π/6 larger diameter × (smaller diameter).2 Character-
ization of the pharmacokinetics of 11 have been already reported by
Faria et al., demonstrating that this compound reaches the maximum
plasma concentration after 5 h from oral administration.38 Character-
ization of the pharmacokinetics of 5 demonstrated that this drug
reaches a plasma concentration of 0.8 μM when orally administered in
mice (20 mg/kg).
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